VivoSeq
Other

Adverse Events

0

Pipeline Programs↗

8

Active Trials↗

6

Companies Involved↗

Adverse Events is an early-stage landscape with 0 programs across 6 companies. The most active players are AbbVie, Mylan Bertek Pharmaceuticals, Novo Nordisk.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

25/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

PreclinicalM

Mylan Bertek Pharmaceuticals

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalA

Akcea Therapeutics

0 programs

PreclinicalR

Raziel Therapeutics Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

59

clinical trials

Completed42 · 71%
Terminated5 · 8%
Recruiting5 · 8%
Active, not recruiting3 · 5%
Unknown status3 · 5%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

59 trials

Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
Recruiting·SSun Yat-sen University·Phase 4·NCT06624696·204 enrolled
Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia.
Recruiting·TTelethon Kids Institute·Phase 4·NCT07000877·200 enrolled
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
Recruiting·AbbVie logoAbbVie·Phase 1·NCT07219030·32 enrolled
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
Recruiting·AbbVie logoAbbVie·Phase 1·NCT07222709·48 enrolled
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
Recruiting·AbbVie logoAbbVie·Phase 1·NCT07232004·87 enrolled
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT07141199·24 enrolled
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT06774313·73 enrolled
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Healthy Adult Participants
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT07071532·20 enrolled
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
Completed·AbbVie logoAbbVie·Phase 1·NCT05556226·40 enrolled
Tamsulosin and the Risk of Serious Adverse Events
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT07274228·14,000 enrolled
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
Completed·AbbVie logoAbbVie·Phase 1·NCT05892757·24 enrolled
Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER
Completed·JJoliet Center for Clinical Research·Phase 4·NCT00211250·20 enrolled
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
Completed·MMylan Bertek Pharmaceuticals·Phase 3·NCT00145171·56 enrolled
The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy
Completed·OOslo University Hospital·Phase 4·NCT00113477·40 enrolled
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
Completed·AbbVie logoAbbVie·Phase 1·NCT05738850·104 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)